Evotec announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (NASH), cardiovascular diseases, and diabetic kidney disease.
Evotec will apply its drug discovery platform, especially in ligand-based design, to seek to design novel, safe and efficacious products to address diabetes and associated morbidities. Once suitable pre-clinical candidates are selected, Novo Nordisk will use Evotec’s INDiGO platform to move through pre-clinical studies to enter IND registration.
“Novo Nordisk is one of the largest, most successful Pharma companies in the world with a proven leadership position in diabetes and obesity,” Dr. Mario Polywka, Chief Operating Officer of Evotec, said. “The integration of our industry-leading discovery and development platform with Novo Nordisk’s deep disease expertise will create a powerful combination that we hope will create a difference for patients with diabetes or obesity. We very much look forward to working with such an innovative partner.”
“Evotec is a highly esteemed company in the field of small molecules and we are very excited about the collaboration,” Dr. Marcus Schindler, senior vice president, Global Drug Discovery, Novo Nordisk, said. “Novo Nordisk is confident that this will open up new possibilities in small molecule drug discovery and development targeting diabetes and obesity with the potential to make a difference for people living with these serious diseases.”
No financial details of the alliance were disclosed.